Astria Therapeutics — Catabasis Pharmaceuticals — Corporate Update (October 2017)
28 slides from Astria Therapeutics's corporate update, Oct 4, 2017
Slide 1: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding our expectations and beliefs about our business, future financial and operating performance, clinical trial plan
Slide 2: Topics of Today's Call
Topics of Today’s Call 3 Duchenne Muscular Dystrophy and Edasalonexent Overview MoveDMD Open-Label Extension Results Phase 3 Edasalonexent Phase 3 Clinical Trial Plan Question and Answer Session
Slide 3: Topics of Today's Call
Topics of Today’s Call 4 Duchenne Muscular Dystrophy and Edasalonexent Overview MoveDMD Open-Label Extension Results Phase 3 Edasalonexent Phase 3 Clinical Trial Plan Question and Answer Session
Slide 4: Duchenne Muscular Dystrophy Unmet Need Continues
Duchenne Muscular Dystrophy Unmet Need Continues Rare disease with well identified patient population – Approximately 15,000 patients in US and 19,000 in EU Initial marketed therapies for small subsets of the patient most patients do not have a targeted therapy available population, Standard of care
Slide 5: DMD Is Characterized by a Predictable Cascade of Discrete Losses of Function and Mobility
DMD Is Characterized by a Predictable Cascade of Discrete Losses of Function and Mobility Milestones Typical DMD Disease Progression o Loss of ambulation eath 0 5 10 15 20 25 30 DMD Patient Age, Years 6 Dr. Craig McDonald, Investor Day 2016 Impaired ability t hop run jump Loss of rise from Loss floo
Slide 6: The Opportunity: Target Product Profile for Edasalonexent
The Opportunity: Target Product Profile for Edasalonexent 7 Indication Foundational treatment of Duchenne muscular dystrophy halting disease progression in boys ages 4+ Mechanism of action Small molecule that inhibits NF-kB Dosing Oral soft gel capsules 3 times per day with meals Efficacy Disease mo
Slide 7: Topics of Today's Call
Topics of Today’s Call 8 Duchenne Muscular Dystrophy and Edasalonexent Overview MoveDMD Open-Label Extension Results Phase 3 Edasalonexent Phase 3 Clinical Trial Plan Question and Answer Session
Slide 8: MoveDMD Phase Trial Design
MoveDMD Phase 2 Trial Design Phase 2 n=31 12 weeks n=17 7 days n=16 Average 39 weeks OPEN-LABEL EXTENSION 16 boys continued 1 boy did not Phase 1 Baseline Phase 2 Baseline Phase 2 Week 12 31 Boys Randomized 15 Boys Newly Enrolled Enrolled 31 boys ages 4 to 7 with confirmed DMD not on corticosteroids
Slide 9: Improvements in Assessments of Muscle Function
Improvementsin Assessments of Muscle Function 10
Slide 10: Prespecified Analysis Approach to Open-Label Assessments of Muscle Function
Prespecified Analysis Approach to Open-Label Assessments of Muscle Function Changes during the control period were measured prior to commencing edasalonexent, either prior to Phase 2 or for the placebo group at the start of the open-label extension, for time periods averaging 39 weeks Comparison of
Slide 11: 10-Meter Walk/Run Speed Stabilized with Edasalonexent Treatment
10-Meter Walk/Run Speed Stabilized with Edasalonexent Treatment 10-Meter Walk/Run 0.20 5 0.18 0.16 0.14 0.12 10 -36 -24 -12 0 Weeks 12 24 36 Disease progression on edasalonexent improved compared with rate of change on control 12 Means ± SEM shown Time (Seconds) Speed (1/Seconds) Edasalonexent 100 m
Slide 12: 4-Stair Climb Speed Stabilized with Edasalonexent Treatment
4-Stair Climb Speed Stabilized with Edasalonexent Treatment 4-Step Climb 0.4 0.3 5 0.2 0.1 10 15 -36 -24 -12 0 Weeks 12 24 36 Disease progression on edasalonexent improved compared with rate of change on control 13 Means ± SEM shown Time (Seconds) Speed (1/Seconds) Edasalonexent 100 mg/kg
Slide 13: Time to Stand Speed Stabilized with Edasalonexent Treatment
Time to Stand Speed Stabilized with Edasalonexent Treatment Time to Stand 0.3 5 0.2 10 0.1 15 -36 -24 -12 0 Weeks 12 24 36 Disease progression on edasalonexent improved compared with rate of change on control 14 Means ± SEM shown Time (Seconds) Speed (1/Seconds) Edasalonexent 100 mg/kg
Slide 14: North Star Ambulatory Assessment Score Stabilized with Edasalonexent Treatment
North Star Ambulatory Assessment Score Stabilized with Edasalonexent Treatment North Star Ambulatory Assessment 25 20 15 10 5 -36 -24 -12 0 Weeks 12 24 36 North Star is a composite endpoint evaluating physical function across 17 tests Disease progression on edasalonexent improved compared with rate
Slide 15: Other Supportive Changes in Measures of Muscle Health
OtherSupportiveChangesin Measures of Muscle Health 16
Slide 16: Muscle Enzymes Significantly Decreased from Baseline on Edasalonexent
Muscle Enzymes Significantly Decreased from Baseline on Edasalonexent Consistent with positive impact on muscle, and supportive of a benefit of edasalonexent Creatine Kinase Alanine Aminotransferase 5000 100 0 0 -5000 10000-15000-20000--100 * -200 12 24 36 12 24 36 Weeks on Edasalonexent Aspartate A
Slide 17: Edasalonexent Significantly Improved Rate of Change of MRI T2 Lower Leg Composite
Edasalonexent Significantly Improved Rate of Change of MRI T2 Lower Leg Composite of 5 Muscles Control Period Compared with MRI T2 increases over time in DMD, as shown for the control period MRI T2 Lower Leg Muscle Composite 0.15 Consistent with positive impact on muscle and a reduction in inflammat
Slide 18: Well Tolerated with No Safety Signals
WellToleratedwith No Safety Signals 19
Slide 19: No Safety Signals and Well Tolerated
No Safety Signals and Well Tolerated No safety signals in MoveDMD trial to date Well tolerated, with majority of adverse events being mild in nature, mostly gastrointestinal –Most common treatment-related adverse events were mild diarrhea –No serious treatment-related adverse events or dose reductio
Slide 20: Age-Appropriate Growth Similar to Standard Growth Curves While on Edasalonexent
Age-Appropriate Growth Similar to Standard Growth Curves While on Edasalonexent Weight 100 50 BMI 100 0 12 24 36 Weeks on Edasalonexent 50 Height 100 0 12 24 36 Weeks on Edasalonexent 50 Boys treated with edasalonexent had age-appropriate increases in height and weight 0 12 24 36 Weeks on Edasalonex
Slide 21: Open-Label Extension Results: Edasalonexent Substantially Slowed DMD Disease Progression
Open-Label Extension Results: Edasalonexent Substantially Slowed DMD Disease Progression Disease progression on edasalonexent improved compared to rate of change in control period – North Star Ambulatory Assessment – Timed function tests 10-meter walk/run, 4-stair climb and time to stand Additional
Slide 22: Topics of Today's Call
Topics of Today’s Call 23 Duchenne Muscular Dystrophy and Edasalonexent Overview MoveDMD Open-Label Extension Results Phase 3 Edasalonexent Phase 3 Clinical Trial Plan Question and Answer Session
Slide 23: Positive MoveDMD Data Support Planned Global Phase 3 Registration Trial
Positive MoveDMD Data Support Planned Global Phase 3 Registration Trial for Edasalonexent Primary Endpoint Design informed by discussions with FDA Key Phase 3 trial components including patient population and endpoints previously evaluated in Phase 2 trial Study Population –Anticipated to be all mut
Slide 24: Thank You
Thank You Thank you to the boys and parents involved in the MoveDMD trial, the trial site staff, patient groups and members of the Duchenne community for their support 25
Slide 25: Edasalonexent: Potential to Slow Disease Progression for All Boys with DMD
Edasalonexent: Potential to Slow Disease Progression for All Boys with DMD Investigational oral disease-modifying product candidate for all patients with DMD, regardless of mutation type Edasalonexent substantially slowed DMD disease progression through 36 weeks Path to registration defined based on
Slide 26: Topics of Today's Call
Topics of Today’s Call 27 Duchenne Muscular Dystrophy and Edasalonexent Overview MoveDMD Open-Label Extension Results Phase 3 Edasalonexent Phase 3 Clinical Trial Plan Question and Answer Session
Slide 27: Topics of Today's Call
Topics of Today’s Call Question and Answer Session Aeatabasis a
Slide 28: Catabasis
WN catabasis
Catabasis Pharmaceuticals — Corporate Update (October 2017) on 6ix